Connect Biopharma - CNTB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.50
  • Forecasted Upside: 3,179.83 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.72
▼ -0.04 (-5.29%)

This chart shows the closing price for CNTB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Connect Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNTB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNTB

Analyst Price Target is $23.50
▲ +3,179.83% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Connect Biopharma in the last 3 months. The average price target is $23.50, with a high forecast of $25.00 and a low forecast of $22.00. The average price target represents a 3,179.83% upside from the last price of $0.72.

This chart shows the closing price for CNTB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Connect Biopharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/2/2022Cantor FitzgeraldReiterated RatingOverweightHigh
5/5/2022Piper SandlerDowngradeOverweight ➝ NeutralHigh
4/1/2022SVB LeerinkInitiated CoverageBuy$22.00High
1/6/2022Piper SandlerLower Target$31.00 ➝ $25.00Medium
1/6/2022SVB LeerinkLower TargetOutperform$32.00 ➝ $22.00Low
7/2/2021CICC ResearchInitiated CoverageOutperform$27.00High
4/13/2021SVB LeerinkInitiated CoverageOutperform$32.00Low
4/13/2021Jefferies Financial GroupInitiated CoverageBuy$27.00Low
4/13/2021Piper SandlerInitiated CoverageOverweightLow
(Data available from 12/4/2017 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/8/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/7/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/5/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/4/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Connect Biopharma logo
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Read More

Today's Range

Now: $0.72
Low: $0.70
High: $0.76

50 Day Range

MA: $0.88
Low: $0.64
High: $1.31

52 Week Range

Now: $0.72
Low: $0.56
High: $5.99

Volume

37,243 shs

Average Volume

35,781 shs

Market Capitalization

$39.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Connect Biopharma?

The following Wall Street analysts have issued research reports on Connect Biopharma in the last year: Cantor Fitzgerald, Piper Sandler, and SVB Leerink LLC.
View the latest analyst ratings for CNTB.

What is the current price target for Connect Biopharma?

2 Wall Street analysts have set twelve-month price targets for Connect Biopharma in the last year. Their average twelve-month price target is $23.50, suggesting a possible upside of 3,179.8%. Piper Sandler has the highest price target set, predicting CNTB will reach $25.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $22.00 for Connect Biopharma in the next year.
View the latest price targets for CNTB.

What is the current consensus analyst rating for Connect Biopharma?

Connect Biopharma currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CNTB will outperform the market and that investors should add to their positions of Connect Biopharma.
View the latest ratings for CNTB.

What other companies compete with Connect Biopharma?

How do I contact Connect Biopharma's investor relations team?

Connect Biopharma's physical mailing address is East R&D Building 3rd Floor Science and Technology Park 6 Beijing West Road, TAICANG F4, 215400. The company's listed phone number is 86-512-5357-7866 and its investor relations email address is [email protected] The official website for Connect Biopharma is www.connectbiopharm.com. Learn More about contacing Connect Biopharma investor relations.